There was no difference in patient characteristics between the two groups (Table 1 ). In the torasemide group, the mean dose of torasemide was 10.1 Ϯ 0.7 mg/day (range, 4 to 16 mg/day).
One month after randomization, there were no differences in hemodynamic parameters. In the furosemide group, the plasma ALD level in the CS was significantly lower than that in the AO (73.1 Ϯ 10.0 pg/ml vs. 56.9 Ϯ 6.5 pg/ml; p Ͻ 0.001). In contrast, there was no difference in plasma ALD levels between the AO and the CS in the torasemide group (85.4 Ϯ 10.5 pg/ml vs. 83.1 Ϯ 11.6 pg/ml) (Fig.  1 ). Plasma procollagen type III aminoterminal peptide in the CS concentration was significantly lower in the torasemide group than that in the furosemide group (0.52 Ϯ 0.03 U/ml vs. 0.67 Ϯ 0.06 U/ml; p Ͻ 0.05). There was a significant negative correlation between the dose of torasemide and the transcardiac gradient (AO-CS) of ALD in the torasemide group (r ϭ Ϫ0.56, p Ͻ 0.01).
We evaluated the transcardiac extraction of ALD as a potential marker of ALD action in the heart (4,5) in patients with CHF. In the furosemide group, the plasma ALD level in the CS was significantly lower than that in the AO. In contrast, there was no difference in plasma ALD level between the AO and the CS in the torasemide group. The transcardiac gradient (AO-CS) of ALD and the extraction ratio of ALD in the AO were significantly lower in the torasemide group than those in the furosemide group. Plasma procollagen type III aminoterminal peptide concentration, a biochemical marker of fibrosis, was significantly lower in the torasemide group than in the furosemide group. These findings may indicate that unlike furosemide, torasemide has an ALD receptor antagonist in the heart. Experimental studies indicate that torasemide inhibits the binding of ALD to its receptor in the cytoplastic fraction of rat kidney (2, 3) . Moreover, the serum potassium level was significantly higher in the torasemide group than in the furosemide group in a large series (i.e., TORIC study). Taken together with our results, the mechanism of the beneficial effect of torasemide in comparison with those of furosemide in the TORIC study may be due to the presence of mineralocorticoid receptor blocker in torasemide. 
Letters to the Editor

Depression and Heart Failure
We read with great interest the recent study by Gottlieb et al. (1) and its related editorial (2) about the important problem of depression in outpatients with heart failure (HF) evaluating its prevalence and the impact of age, race, and gender. We would like to add two comments. First, we believe that the duration of evolution of HF symptoms is a simple and important parameter that should have been taken into account. A depression is likely to occur with time when the patient realizes the true chronicle aspect of its disease, its severity, and the overall limitation in physical activity and well-being. The number of hospitalizations across the years may also play a role, and these aspects of the disease might have been included in the prediction model of Gottlieb et al. (1) .
Second, the diagnosis of depression should particularly be addressed when one considers the implantation of a cardioverterdefibrillator (ICD). Although the device is usually well accepted despite fear of being shocked, patients with an ICD have high levels of anxiety and depressive symptoms (3). The ICD shocks might have the potential to cause psychological disorders. This may become a relatively frequent problem considering the preliminary results of the Sudden Cardiac Death-Heart Failure Trial (SCD-HeFT) in which treatment with an ICD compared with placebo and amiodarone was associated with a reduction in all-cause mortality in a large population of patients with heart failure of all etiologies and with a left ventricular ejection fraction Ͻ35% (4).
Thus, considering the potential association among ICD placement, electrical shock from the ICD, and depression, we should probably collect information regarding this association in the evaluation of such patients. 
